Dasatinib 140mg tablets
Requires a prescription from a doctor or prescriber
Cytotoxic drugs
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Dasatinib
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Dasatinib
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
6 branded products available
MHRA licensed products
View all licensed products for Dasatinib on the MHRA register
Sprycel 140mg tablets
Dasatinib 140mg tablets
Dasatinib 140mg tablets
Dasatinib 140mg tablets
Dasatinib 140mg tablets
WHO defined daily dose (DDD)
100 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Dasatinib
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(7)
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA714)
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
82 found
Half-life
3-5 hours
Mechanism
Dasatinib is a tyrosine kinase inhibitor with several targets.
Food interactions
3 warnings
Human targets
23 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
15 mg/d
Half-life
3-5 hours
[L45171]
Protein binding
96%
[L45171]
Volume of distribution
2505 L
[L45171]
Metabolism
5%
Elimination
10 days
Clearance
363.8 L/h
[L45171]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226][A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance.[A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171][L45186]
[L45171]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1543 interactions
[L45171]
Acute overdose in animals was associated with cardiotoxicity.
In rodents, ventricular necrosis and valvular/ventricular/atrial hemorrhage were detected at single doses higher than or equal to 100 mg/kg (600 mg/m2). In monkeys receiving single doses higher than or equal to 10 mg/kg (120 mg/m2), there was a tendency for increased systolic and diastolic blood pressure.
[L45171]
In rats, the oral LD50 of dasatinib is 50-100 mg/kg, and in monkeys, it is 25-45 mg/kg.
[L45176]
How the body processes this drug — absorption, distribution, metabolism, and elimination
The Tmax of dasatinib is between 0.5 and 6 hours following oral administration. Following a single dose of 100 mg, a high-fat meal increases the AUC of dasatinib by 14%.
[L45171]
[L45171]
[L45171]
[L45171]
[L45171]
Five pharmacologically active dasatinib metabolites have been identified: M4, M5, M6, M20 and M24. M4, M20, and M24 are mainly generated by CYP3A4, M5 is generated by FMO3, and M6 is generated by a cytosolic oxidoreductase.
[A257226][A15000]
M4 is equipotent to dasatinib and represents approximately 5% of the AUC. However, it is unlikely to play a major role in the observed pharmacology of dasatinib.
[A257226][L45171]
M5 and M6 are more than 10 times less active than dasatinib and are considered minor circulating metabolites.
[A257226]
[L45171]
[L45171]
Proteins and enzymes this drug interacts with in the body
Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9 .
PMID:22810897
Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling.
Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death.
In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' .
PMID:28428613
ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired.
Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks.
ABL1 also acts as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum.
Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner (By similarity).
Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity)
PMID:34234773
Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families.
Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments.
Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN) (Probable). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN) .
PMID:21411625
In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1).
SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1 (Probable). Phosphorylates PKP3 at 'Tyr-195' in response to reactive oxygen species, which may cause the release of PKP3 from desmosome cell junctions into the cytoplasm .
PMID:25501895
Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors (By similarity). Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1 .
PMID:11389730
Plays a role in EGF-mediated calcium-activated chloride channel activation .
PMID:18586953
Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'.
Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor (Probable). Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus .
PMID:7853507
Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2.
Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function .
PMID:14585963 PMID:8755529
Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase .
PMID:12615910
Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation .
PMID:16186108
Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731' .
PMID:20100835 PMID:21309750
Enhances RIGI-elicited antiviral signaling .
PMID:19419966
Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376' .
PMID:14585963
Phosphorylates BCAR1 at 'Tyr-128' .
PMID:22710723
Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity .
PMID:20525694
Phosphorylates synaptic vesicle protein synaptophysin (SYP) (By similarity). Involved in anchorage-independent cell growth .
PMID:19307596
Required for podosome formation (By similarity).
Mediates IL6 signaling by activating YAP1-NOTCH pathway to induce inflammation-induced epithelial regeneration .
PMID:25731159
Phosphorylates OTUB1, promoting deubiquitination of RPTOR .
PMID:35927303
Phosphorylates caspase CASP8 at 'Tyr-380' which negatively regulates CASP8 processing and activation, down-regulating CASP8 proapoptotic function PMID:16619028
Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues.
Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis
Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK.
Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK.
Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR.
Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with FYB2 PMID:27335501
Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration.
Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis. Catalyzes phosphorylation of organic cation transporter OCT2 which induces its transport activity PMID:26979622
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562
Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388
In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239
Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).
Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042
In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).
In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response
ATC L01EA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Dasatinib
Additional database identifiers
Drugs Product Database (DPD)
20122
ChemSpider
2323020
BindingDB
13216
PDB
1N1
ZINC
ZINC000003986735
HUGO Gene Nomenclature Committee (HGNC)
HGNC:76
GenAtlas
ABL1
GeneCards
ABL1
GenBank Gene Database
X16416
GenBank Protein Database
28237
Guide to Pharmacology
1923
UniProt Accession
ABL1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11283
GenAtlas
SRC
GeneCards
SRC
GenBank Gene Database
AL133293
GenBank Protein Database
10635153
Guide to Pharmacology
2206
UniProt Accession
SRC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3386
GenAtlas
EPHA2
GeneCards
EPHA2
GenBank Gene Database
M59371
GenBank Protein Database
181944
Guide to Pharmacology
1822
UniProt Accession
EPHA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6524
GenAtlas
LCK
GeneCards
LCK
GenBank Gene Database
X05027
GenBank Protein Database
36808
Guide to Pharmacology
2053
UniProt Accession
LCK_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12841
GenAtlas
YES1
GeneCards
YES1
GenBank Gene Database
M15990
GenBank Protein Database
181268
Guide to Pharmacology
2284
UniProt Accession
YES_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6342
GenAtlas
KIT
GeneCards
KIT
GenBank Gene Database
X06182
GenBank Protein Database
34085
Guide to Pharmacology
1805
UniProt Accession
KIT_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8804
GenAtlas
PDGFRB
GeneCards
PDGFRB
GenBank Gene Database
J03278
GenBank Protein Database
189732
Guide to Pharmacology
1804
UniProt Accession
PGFRB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4037
GenAtlas
FYN
GeneCards
FYN
GenBank Gene Database
M14333
GenBank Protein Database
338228
Guide to Pharmacology
2026
UniProt Accession
FYN_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1014
GeneCards
BCR
UniProt Accession
BCR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11367
GenAtlas
STAT5B
GeneCards
STAT5B
GenBank Gene Database
U48730
GenBank Protein Database
6981726
UniProt Accession
STA5B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:77
GenAtlas
ABL2
GeneCards
ABL2
GenBank Gene Database
M35296
GenBank Protein Database
178993
Guide to Pharmacology
1924
UniProt Accession
ABL2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1133
GenAtlas
BTK
GeneCards
BTK
GenBank Gene Database
X58957
GenBank Protein Database
312467
Guide to Pharmacology
1948
UniProt Accession
BTK_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7982
GeneCards
NR4A3
Guide to Pharmacology
631
UniProt Accession
NR4A3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2444
GenAtlas
CSK
GeneCards
CSK
GenBank Gene Database
X60114
GenBank Protein Database
30315
Guide to Pharmacology
1994
UniProt Accession
CSK_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3389
GeneCards
EPHA5
Guide to Pharmacology
1825
UniProt Accession
EPHA5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3395
GenAtlas
EPHB4
GeneCards
EPHB4
GenBank Gene Database
U07695
Guide to Pharmacology
1833
UniProt Accession
EPHB4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3697
GeneCards
FGR
Guide to Pharmacology
2024
UniProt Accession
FGR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3955
GeneCards
FRK
Guide to Pharmacology
2025
UniProt Accession
FRK_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5241
GeneCards
HSPA8
GenBank Gene Database
AB034951
GenBank Protein Database
11526573
UniProt Accession
HSP7C_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6735
GeneCards
LYN
GenBank Gene Database
M16038
GenBank Protein Database
307144
Guide to Pharmacology
2060
UniProt Accession
LYN_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17797
GeneCards
MAP3K20
Guide to Pharmacology
2289
UniProt Accession
M3K20_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6876
GenAtlas
MAPK14
GeneCards
MAPK14
GenBank Gene Database
L35263
GenBank Protein Database
603917
Guide to Pharmacology
1499
UniProt Accession
MK14_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9238
GenAtlas
PPAT
GeneCards
PPAT
GenBank Gene Database
D13757
GenBank Protein Database
219459
UniProt Accession
PUR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2595
GeneCards
CYP1A1
GenBank Gene Database
K03191
GenBank Protein Database
181276
Guide to Pharmacology
1318
UniProt Accession
CP1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2597
GenAtlas
CYP1B1
GeneCards
CYP1B1
GenBank Gene Database
U03688
GenBank Protein Database
501031
Guide to Pharmacology
1320
UniProt Accession
CP1B1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3771
GeneCards
FMO3
GenBank Gene Database
M83772
GenBank Protein Database
188631
UniProt Accession
FMO3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:74
GenAtlas
ABCG2
GeneCards
ABCG2
GenBank Gene Database
AF103796
GenBank Protein Database
4185796
Guide to Pharmacology
792
UniProt Accession
ABCG2_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
5 active patents, 5 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: